| Overview |
| bs-0050R-Cy5 |
| Caspase-9 Polyclonal Antibody, Cy5 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Caspase-9 subunit p35 |
| 271-314/416 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 842 |
| P55211 |
| Cytoplasm, Nucleus |
| MCH6; APAF3; APAF-3; PPP1R56; ICE-LAP6; Caspase-9; CASP-9; Apoptotic protease Mch-6; Apoptotic protease-activating factor 3; ICE-like apoptotic protease 6; CASP9 |
| Involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Promotes DNA damage-induced apoptosis in a ABL1/c-Abl-dependent manner. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP). Isoform 2 lacks activity is an dominant-negative inhibitor of caspase-9. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz